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Abstract 
Multiparametric MRI for evaluation of tumour treatment response 
Studies of 177Lu-octreotate therapy of neuroendocrine tumour 
Mikael Montelius 
Department of Radiation Physics, Institute of Clinical Sciences,  
Sahlgrenska Academy at University of Gothenburg, Sweden, 2016 
Clinical assessment of tumour response to treatment largely relies on estimates of tumour size 
by, e.g., measuring the largest tumour diameters on magnetic resonance (MR) or computed 
tomography (CT) images, weeks or months after treatment. However, most tumours are 
heterogeneous, and treatment may result in different effects in different parts of the tumour. 
Therefore, non-invasive methods sensitive to biological effects that precede changes in 
tumour size would improve our understanding of tumour biology and therapeutic effects, 
facilitate personalized treatments and speed up development of anti-cancer therapeutics. MR 
methods have the potential to provide non-invasive imaging biomarkers of the relevant 
tumour biology, but the understanding of the information provided by MR methods is still 
limited. 
The aim of this project to was to improve the understanding and evaluate the feasibility of 
multiparametric MR methods for therapy response assessment of tumours after radionuclide 
therapy.  
Mice xenografted with human neuroendocrine tumours received 15 MBq 177Lu-octreotate i.v. 
on day 0, and MR imaging experiments were performed on days -1, 1, 3, 8 and 13, using 
dynamic contrast enhanced-, quantitative T1 and T2*- and diffusion weighted MR on a 7T 
small animal MR system. Optimization studies were performed to improve tissue model 
parameter estimates, and to ensure accurate MR based tumour volume estimation for response 
verification. MR parameter maps were spatially registered to corresponding histologically 
stained tumour section for correlation analysis, and tumour tissue samples were analysed 
using quantitative proteomics.   
Several statistically significant correlations were found between MR parameters and 
histological tumour characteristics, as well as with proteins associated with radiobiological 
effects on tumours, and collectively evaluated they provided information on apoptotic and 
proliferative activity, microvascular density and fibrosis in tumours, which are all important 
prognostic tumour characteristics. Spatial and temporal MR parameter variations before and 
after therapy seem to be predictive of tumour shrinkage or stabilization. Most effects on MR 
parameters were seen already one day after treatment initiation.  
This work demonstrates the feasibility of multiparametric MR for therapy response 
assessment in an animal tumour model, and highlights the importance of spatial and temporal 
evaluation of the MR parameters. Future efforts should include improvement of methods for 
spatial registration of in vivo MR images and ex vivo histological sections. For clinical 
applications, MR acquisition times need to be reduced.  
Keywords: Cancer, Functional imaging, IVIM, MRI, DWI, DCE, histology, 177Lu-octreotate, small 
intestine neuroendocrine tumour, NET, diffusion, perfusion, semi-quantitative, proteomics, ionizing 
radiation, biology, imaging biomarker 
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Populärvetenskaplig sammanfattning 
Idag vet man att tumörer oftast är heterogena, vilket innebär att vissa områden i 
tumören kan svara bra på behandling, medan andra svarar sämre. Detta kan till 
exempel bero på varierande genomblödning (perfusion), vilket kan hindra transport 
av läkemedel till tumörvävnaden, eller syrebrist, vilket försämrar effekten av 
strålning. Man kan därför inte se tumören som en enkel, homogen massa av 
tumörceller, men de metoder som är kliniskt tillgängliga idag för att säkerställa att 
tumören svarar på behandling bygger på ett sådant koncept. Storleken på tumören 
skattas genom att man mäter dess diametrar t.ex. på magnetresonans (MR)- eller 
datortomografi (DT)-bilder, och man måste vänta länge mellan mätningarna för att 
säkerställa svar, eftersom metoden har låg noggrannhet och känslighet för små 
förändringar i tumörvolym. Det innebär stora risker för patienten, eftersom 
ineffektiv behandling upptäcks i ett sent skede, vilket kan innebära sämre chanser 
till bot. Om det istället fanns metoder för att mäta de biologiska effekterna på 
tumören som sker före tumörvolymen påverkas, skulle man tidigare upptäcka 
ineffektiv behandling, bespara patienten onödigt lidande och kraftigt minska 
kostnaderna för samhället. Heterogeniteten kräver dock att metoderna visar hur alla 
delar av tumören svarar, och man behöver kunna studera utvecklingen i tumören 
före, under och efter behandlingen, vilket kräver att metoderna är icke-invasiva. När 
effekter av behandling studeras bör bildgivande metoder i sig inte ge någon stråldos 
till tumören, eftersom det kan påverka effekterna som studeras. Om vi hade tillgång 
till sådana metoder skulle vår kunskap om tumörbiologin och behandlingseffekter 
öka, och det skulle innebära snabbare framställning och test av nya 
cancerläkemedel.   
MR-tekniker är icke-invasiva, och de kan användas för att avbilda hela tumören med 
mycket god detaljupplösning och bildkontrast. De har dessutom visat stor potential 
för mätning av relevanta biologiska effekter efter tumörbehandling, men förståelsen 
av kopplingen mellan de vävnadsparametrar man kan härleda från olika MR-
tekniker och den underliggande tumörbiologin är begränsad. Syftet med detta 
avhandlingsprojekt var därför att öka förståelsen av den information som erhålls från 
olika MR-avbildningar av tumören, och därmed öka möjligheterna att använda dessa 
metoder för att mäta tumörsvar efter radionuklidterapi. 
Som tumörmodell användes naken mus med human, neuroendokrin tunntarmstumör 
växande under huden. Tumörerna avbildades med flera olika MR-tekniker dagen 
före behandling (dag -1), i ett MR-system (7T) för smådjur. Dag 0 injicerades 15 
MBq 177Lu-octreotate i en svansven, och dag 1, 3, 8 och 13 upprepades MR-
avbildningarna. Efter den sista avbildningen avlivades djuret, tumören delades 
parallellt med ett av de avbildade planen i tumören, och anatomiska riktningar 
färgkodades med vävnadsbläck i tumörkanterna. Dessa färgmarkeringar användes 
sedan för att matcha histologiskt infärgade och digitaliserade vävnadssnitt med MR-
parameterbilder. Innan vävnadsparametrar beräknades från MR-bilderna, 
optimerades vissa modellanpassningsmetoder, bl.a. med hjälp av datorsimuleringar, 
för att säkerställa god kvalitet på parametrarna. En MR-avbildningsmetod 
optimerades för bestämning av tumörvolym med hög noggrannhet, vilket användes 
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för att verifiera tumörsvar. Vävnadsparameterkartor beräknades från MR-
avbildningarna, och med hjälp av digital bildregistrering mot motsvarande 
histologiskt infärgat tumörsnitt undersöktes sambanden mellan MR-parametrar och 
tumörbiologi på pixelnivå. MR-parametrar jämfördes även mot proteinuttryck, som 
framställdes med kvantitativ proteomik på vävnadsprover. 
Flera statistiskt signifikanta samband kunde påvisas mellan MR-parametrar och de 
biologiska egenskaper hos tumören som speglades i histologiparametrarna, men 
även mellan MR-parametrar och nivåer av proteinuttryck för proteiner som 
associerats med radiobiologiska effekter i tumörer. Den sammanlagda informationen 
som erhölls från MR-parametrarna kunde användas för att påvisa pågående apoptos 
(programmerad celldöd som t.ex. kan ske efter strålningsinducerad DNA-skada), 
proliferation (celldelning/tillväxt), mikrovaskulär densitet (förekomst av 
kärl/kapillärer vilket krävs för t.ex. syresättning) och fibros (vävnadsform som kan 
uppstå efter tidigare celldöd) vilka är kliniskt viktiga prognostiska tumörparametrar. 
Variationer av MR-parametrar inom tumören, och över tid efter behandling, kunde 
användas för att förutsäga vilka tumörer som skulle krympa och vilka som tillfälligt 
skulle stanna upp eller växa långsammare, och de flesta förändringarna i MR-
parametrarna kunde ses redan dagen efter behandlingen. En viktig observation var 
att flera MR-parametrar som kunde användas för att skilja de olika svarande 
tumörgrupperna från varandra endast visade tillfälliga förändringar under 
uppföljningstiden, och att vissa parametrar endast kunde användas för att skilja 
grupperna om de analyserades lokalt i tumören, t.ex. i mer perifera delar, medan ett 
medelvärde av parametern över hela tumören inte förmådde skilja grupperna.   
I detta arbete visas att det är möjligt att, genom att utläsa flera MR-parametrar från 
samma avbildningstillfälle, få ut viktig information om hur tumören svarar på 
behandling, och att det är viktigt att läsa ut informationen regionalt, och inte bara 
som ett medelvärde för hela tumören, samt att viktig information finns i hur 
parametrarna varierar efter behandlingen, såväl som i parametrarnas värden före 
behandling. För fortsatta studier inom detta område behövs bättre metoder för att 
säkerställa att MR-parametrar matchas bra mot vävnaden som analyseras efter att 
tumören avlägsnats. Innan metoderna kan användas kliniskt måste dessutom 
avbildningsteknikerna bli snabbare, och de biologiska kopplingarna som visas i detta 
arbete måste verifieras i flera studier på djur, samt i patienter.  
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Background 
Cancer 
Epidemiology 
In 2012, the estimated number of new cancer cases worldwide was 14.1 
million, and the corresponding number of cancer deaths was 8.2 million. In 
Europe, the corresponding numbers were 3.7 and 1.9 million cases. Cancer 
now causes more deaths than coronary heart disease or stroke, and WHO 
expects an increasing cancer burden over the next decades [1, 2]. 
Hallmarks of cancer 
In 2000, Hanahan and Weinberg [3] proposed six distinctive and 
complementary biological capabilities, or hallmarks, that are acquired by 
normal cells during the multistep process that lead to the formation of 
malignant tumour cells and cancer development:  
Sustained proliferative signalling 
One of the most fundamental hallmarks is the capability of tumour cells to 
grow and divide (proliferate). In normal tissues, this process is carefully 
controlled by the production and release of substances that tells the cell to 
enter the growth-and-division cell cycle. Tumour cells acquire capabilities to 
e.g. produce their own growth substances or stimulate normal cells in the 
tumour microenvironment (TME) to support their proliferation [3].  
Evading growth suppressors 
Tumour cells must also evade the multiple, redundant and powerful 
programs constructed to suppress excessive cell proliferation, as well as the 
contact inhibition that supress further proliferation in normal cells when cell-
to-cell contact is reached in dense cell populations [3]. 
Resisting programmed cell death  
Another natural process that supports homeostasis in normal tissues is the 
programmed cell death by apoptosis. Apoptosis is triggered by e.g. 
physiological stress or DNA damage, whereby the cell is contracted, 
disassembled and removed by phagocytosis. The tumour cell avoids 
apoptosis in several ways, the most common being the loss of the TP53 
tumour suppressor function, which is considered the guardian of the genome 
by its ability to detect and eliminate damaged DNA [3].  
Enabling replicative immortality 
Tumour cells must bypass the limitation of the number of cell growth-and-
division cycles they can enter, which, in normal cells, is limited by the 
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shortening of the telomeres by each division. The telomeres protect the ends 
of the chromosomes, and when they are too short, chromosomal DNA is 
threatened and the cells enter apoptosis. In the majority of cancer cells, 
however, telomerase is present in abnormal levels. Telomerase is a 
specialized DNA polymerase with the capability to add telomere segments to 
the ends of the telomeres and thereby immortalize them [3]. 
Inducing angiogenesis  
Tumours quickly outgrow the vasculature supporting tumour cells with 
oxygen and nutrients. The deprived tumour cells start signalling for blood 
vessel formation from existing vessels (angiogenesis) by releasing e.g. 
vascular endothelial growth factor (VEGF). VEGF bind to the surface of the 
endothelial cells lining the existing vessels, which in turn start proliferating 
to form the new vessels. In contrast to normal tissues, the pro-angiogenic 
signalling will continue in an uncontrolled fashion. This causes chronic 
cycles of sprouting and branching of the tumour vasculature and results in a 
highly chaotic and immature vasculature network of excessive branching, 
leakiness, shunts and micro haemorrhaging [3]. 
More than a decade later, some additional hallmarks have emerged, but the 
original six are still considered to provide a foundation for the understanding 
of the complex biology underlying cancer, and they are also widely 
investigated as targets for successful tumour treatment [4].  
Tumour microenvironment and heterogeneity 
Solid tumours are increasingly being recognized as complex tissues, in 
contrast to the earlier view of tumours as a collection of cancer cells of 
relatively homogeneous nature. A variety of cell types and subtypes 
constitute tumour stroma and parenchyma (tumour cells), but the interactions 
between the tumour and stromal cells are far from understood. Together, 
they constantly remodel the extracellular matrix according to their needs for 
growth and progression [5]. A complete understanding of the biology of the 
tumour thus requires the understanding also of the TME. Solid tumours 
typically comprise regions of high proliferative activity and reduced 
apoptosis, which result in increased cell density. On the contrary, the rapid 
growth and poorly organized and dysfunctional vascularization and blood 
supply result in regions with reduced proliferation, hypoxia and necrosis [4, 
6, 7]. Furthermore, the microvasculature is often highly permeable and 
leaky, which in combination with poor lymphatic drainage and rapid growth 
within the encapsulated tumour volume contribute to an elevated interstitial 
fluid pressure (IFP) throughout the tumour. Typically, IFP is higher in 
central tumour regions, but rapidly normalize at the tumour edges [8-11]. 
Increased IFP and inadequate vasculature impedes the trans-capillary and 
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interstitial transport of oxygen and compounds such as nutrients and 
therapeutic agents to tumour cells [12-14]. Tumour cells in regions of  
hostile environment adapt by, e.g., switching to anaerobic metabolism, and 
they progress to more malignant states by natural selection [5]. The 
heterogeneity imposes many challenges for therapeutic success, such as 
delivery of the therapeutic agents to poorly perfused regions, radioresistance 
due to hypoxia and regional response assessment. 
This may also promote metastatic spread, since lactic acid is produced in 
large amounts under anaerobic metabolism, leading to acidification and loss 
of E-cadherin, which is important for cell-to-cell adhesion.  
Neuroendocrine tumour (NET) 
Neuroendocrine tumours (NETs) represent many different malignancies that 
arise from neuroendocrine cells in different parts of the body. Small intestine 
NETs are rare, but with significantly increasing incidence during the last 
decades [15]. The primary tumour is typically slow growing, but at the time 
of diagnosis, mesenteric, liver or more distant metastases are almost always 
present, resulting in inoperable disease. NETs are typically angiogenic and 
vascular, and express somatostatin receptors, which makes them suitable for 
imaging with radiolabelled somatostatin analogues, such as 111In-octreotide, 
but also for therapy using e.g. 177Lu-octreotate [16-18]. 
Tumour model 
To study the effects of therapy on tumours, animal models are often used 
since it is possible to reduce the influence of genetic heterogeneity and 
environmental factors that complicate the interpretation of the results. 
Furthermore, analysis on cell cultures alone does not include the interaction 
of tumour cells with TME, and although the tumour does not grow in its 
original environment, it more closely mimics the human disease. Mice are 
advantageous since they are small, easy to handle during experiments, breed 
fast and have a well-known genome. In the present thesis, most studies were 
performed on Balb/c nude mice with xenografts from a human small 
intestine NET. This type of mouse is immunodeficient due to the lack of T-
cells, which allows the tumours to grow. It is therefore a suitable animal to 
work with when analysing the effects of tumour therapy, especially when 
using MR equipment dedicated to small animal imaging.  
Targeted radionuclide therapy 
Surgery and/or radiotherapy are the only curative options for solid tumour 
cancers, but unfortunate locations of tumours or metastatic disease may 
make external radiotherapy or surgery impossible [19]. In targeted 
radionuclide therapy, a radionuclide is coupled to e.g. a peptide or an 
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antibody that bind specifically to the cells of the tumour. If the physical 
range of the radioactively emitted particle is well suited for the size of the 
tumour, only tumour cells and TME are irradiated, and side effects on 
nearby healthy tissue, that made external radiotherapy impossible, are 
reduced [18, 19].  
Radiobiological effects on tissue 
Ionizing radiation induces damage to DNA, either directly or indirectly via 
the production of reactive oxygen species (ROS), in addition to several other 
effects on intra- and intercellular signalling pathways, which optimally lead 
to tumour cell death [19]. Beside effects on DNA, other radiation-induced 
mechanisms can influence the curative effect, such as effects on protein or 
membrane integrity, but also effects that influence invasiveness and 
metastatic potential [19, 20]. Knowledge about radiobiological effects is 
based largely on external radiation therapy. The radiobiology of radionuclide 
therapy differs, e.g. due to inhomogeneous irradiation often including mixed 
fields, low absorbed dose rates and long exposure times, and must be further 
investigated in order optimize radionuclide therapy [19]. 
177Lu-octreotate therapy 
177Lu-octreotate is primarily a beta emitting compound with great affinity for 
somatostatin receptors 2, 3 and 5, which has shown great promise for 
treatment of patients with inoperable NET disease regarding tumour 
regression, increased overall survival and improved quality of life, and it has 
shown little side effects [21, 22]. There are, however, few curative results 
reported, and few prognostic indicators for the individual patient. The high 
cure rates in animals transplanted with human NETs indicate that the 
treatment needs optimization, such as individualized treatment, 
radiosensitizing of tumour tissue, methods to increase receptor expression 
and combinations with other therapies, but with maintained or reduced 
normal tissue toxicity [18]. 
Therapy response assessment 
The heterogeneity of tumours is probably one of the major reasons for 
therapeutic failures. Characterization of a cancer requires histological 
analysis of tumour biopsies and is critical for medical decision making, but 
biopsies are typically based on focally sampled regions [23]. Unfortunate 
biopsy sampling may therefore result in important diagnostic information 
being missed. Even if correct information is acquired, different tumours may 
respond differently to the same therapy. Ideally, tumour response would be 
evaluated early after onset of treatment. This would reduce costs, risks and 
unnecessary suffering due to inefficient treatment. To facilitate longitudinal 
follow-up, non-invasive assessment methods would be preferred. Imaging 
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can provide accurate measurements of tumour volume, but radiation therapy 
may not affect tumour size immediately, which makes assessments based on 
tumour size alone insufficient for early response assessment. Instead, the 
methods should be sensitive to early treatment-induced effects on the tumour 
cells, physiology, metabolism or TME [24]. Such methods would provide 
valuable guidance to suspicious tumour regions during biopsy for diagnosis, 
and provide surrogate markers for treatment-induced radiobiological effects 
during follow-up [25]. 
Imaging for therapy response assessment 
Imaging has the advantage of offering an overview of the heterogeneous 
tumour, often in three dimensions. Several quantitative imaging techniques 
are already used clinically, and provide biomarkers reflecting structural, 
physiological and metabolic information of the tumour. Magnetic resonance 
(MR) imaging (MRI), single photon emission computed tomography 
(SPECT), scintigraphy using gamma camera, ultrasound (US) and [18F]-2-
fluoro-2-deoxyglucose positron emission tomography (FDG-PET) are some 
examples [26]. 
Scintigraphy and SPECT are imaging techniques that utilize the tumour 
specific uptake of certain radiopharmaceutical to image e.g. biological and 
metabolic changes in tumours [27, 28]. They are often used to complement 
other imaging techniques with higher spatial resolution in oncology. Several 
SPECT tracers are of interest for tumour imaging, such as apoptosis specific 
tracers based on annexin V [27].  
PDG-PET utilizes the increased metabolism of tumour cells to accumulate 
the radioactive positron emitting nuclide 18F in metabolic active tumours 
[25]. It is a sensitive tool for characterization of tumours and detection of 
metastases, and has e.g. been shown to detect changes in glycolytic rate in 
gastrointestinal stromal tumours already 24 h after Imatinib mesylate 
(Glivec) treatment, several weeks before effects were seen on tumour 
volumes [29]. However, the limited spatial resolution in PET makes it 
difficult to use as a single imaging modality.  
Integrated systems combining e.g. metabolic information from PET or 
SPECT with computed tomography (CT) takes advantage of the 
morphological information gained from CT. PET/CT has provided 
synergistic effect e.g. in staging of lung cancer, where MRI is still 
challenging due to susceptibility effects [30, 31]. PET, SPECT and CT 
utilize ionizing radiation, which can be confounding in studies on effects of 
radiotherapy. PET imaging in highly energetic organs such as the brain, or 
close to locations of FDG accumulation such as in the pelvis around the 
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bladder is difficult due to the high background signal. Inflammation, often 
present in and around tumours, may also present increased glucose 
metabolism, which may reduce tumour specificity in PET imaging [32].  
The synergistic value of the abovementioned techniques is largely dependent 
on proper alignment or fusion of images, which is often achieved by the 
hybrid systems available, such as PET/CT or MRI/PET where the imaged 
object remains in position during sequential acquisition using both 
modalities.  
MR methods for response assessment 
MR techniques provide images with unparalleled soft tissue contrast and 
excellent spatial resolution. Manipulations of the pulse sequences can also 
make the techniques sensitive to functional and physiological states and 
processes within the imaged tissue, such as blood perfusion, water molecular 
diffusion, metabolic composition and pH status, several of which are altered 
in tumour tissue, and affected by therapy [33]. MR thus offers a means to 
non-invasively probe different aspects of the tumour parenchyma and TME 
before, during and after treatment.  
Until now, however, the potential of the MR methods is not fully explored, 
since tissue parameters derived from the MR methods are mostly evaluated 
as whole tumour average values, which does not account for intra-tumour 
heterogeneity. The non-invasiveness of the methods could also be better 
utilized, since it allows studies of the dynamical behaviour of the tissue 
parameters. Most importantly, evaluating the spatial and temporal variations 
of multiparametric MR information on tumour tissue in response to therapy 
would probably provide new insights into the biological meaning of the MR 
parameters, as well as the tumour biology. To our knowledge, few such 
studies have yet been performed. One application that would probably gain 
much from such evaluations is radionuclide therapy. As opposed to external 
radiotherapy, on which most radiobiology is built, radionuclide therapy is 
inhomogeneous, prolonged and may involve mixed radiation types. The 
inhomogeneity may be caused by differences in peptide or antibody uptake 
and availability due to inadequate vasculature [20, 34]. Methods to assess 
the tumour response to such therapies thus require the versatility offered by 
the proposed multiparametric MR methods. An introduction to the separate 
MR methods that will be included in this thesis is given below. 
Diffusion weighted MRI 
Diffusion weighted MRI (DWI) is a non-invasive imaging technique 
sensitive to the random motion of water, such as the Brownian motion of 
water molecules (diffusion), imposing an exponential attenuation of the MR 
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signal amplitude with increased diffusion sensitization (b-value). The 
apparent diffusion coefficient (ADC) can thus be quantified by fitting a 
simple mono-exponential model to the DWI signal with increasing b-value. 
On the timescale of a DWI experiment, the tissue water diffusion is 
restricted by the presence of e.g. cell membranes, which effectively reduces 
the attenuating effect of the diffusion sensitization on the MR signal. This 
makes DWI interesting for tumour treatment assessment, since higher ADC 
(less restrictions on water diffusion) would indicate reduced cell density and 
vice versa. However, capillary microcirculation within the DWI voxel, 
encompassing thousands of randomly orientated capillary segments, will 
mimic molecular diffusion on a macroscopic level, and impose an additional 
exponential attenuation on the MR signal, resulting in a positively biased 
diffusion measurement. The intravoxel incoherent motion (IVIM) model 
[35] treats tissue water molecular diffusion (D) and perfusion related 
“pseudo-diffusion” (D*) as two separate compartments. IVIM-DWI thus 
allow quantification of both these phenomena separately, in addition to the 
fractional contribution of D* to the signal decay with increasing b-value, 
referred to as the perfusion fraction (f). The IVIM model thus provides a 
means to quantify D (ADC without perfusion bias) and perfusion related 
effects non-invasively, without the use of contrast media injection. Both the 
ADC and IVIM models are obviously simplistic since there are probably 
more than just two distinct compartments of incoherent motion in tissues 
that affect the diffusion weighted MR signal, and more advanced models 
exist (e.g. [36]). However, the two compartments described here are 
probably the most influential on the MR signal measured in vivo, outside the 
brain, where e.g. motion signal-to-noise ratio (SNR) and susceptibility 
effects impose limitations on the quality of the measured signal and the 
complexity of the models applied. 
Considerations regarding bi-exponential model fitting 
The IVIM model is bi-exponential, which makes it more prone to errors 
introduced by the model fitting algorithm compared with mono-exponential 
models such as the ADC model. In tumours, there are likely regions with 
low perfusion fraction, which essentially makes the bi-exponential model 
over-parameterized, which may in turn yield unstable results. Several 
methods have been proposed as alternatives to the least squares fitting 
methods commonly applied to estimate IVIM parameters. Bayesian model 
fitting has been proposed as a robust alternative [37]. Barbieri et al. [38] 
compared several model fitting strategies commonly found in the literature, 
including the most common least squares and stepwise methods, and 
demonstrated the superiority of the Bayesian in this context. Bayesian 
methods require an a priori distribution of the model parameters before 
fitting. Commonly, a non-informative and truncated uniform or reciprocal 
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prior distribution is used. A shrinkage prior was suggested to improve the 
fitting of D*, which often results in noisy estimates [39]. The output of a 
Bayesian model fit is a marginalized probability distribution of each 
parameter, as opposed to the point estimates resulting from least squares 
fitting. Thus, a measure of e.g. central tendency is required in order to make 
the results more comprehensible. Both mean, median and mode values have 
been used to describe the central tendency in the context of Bayesian model 
fitting [37, 39, 40]. The choice of prior distributions and central tendency 
representation is of particular importance in the low SNR setting, 
characteristic of diffusion weighted imaging, and the alternatives should be 
evaluated in order to optimize the parameter estimates. 
DWI is a generally accepted oncological imaging technique e.g. for 
differentiating benign from malignant lesions or monitoring radiation 
treatment response. It is simple to use and does not require endogenous 
contrast media, which enables its use in patients with impaired renal function 
[41].  
In the research setting, evidence suggests that ADC has a great potential as a 
surrogate marker for tumour control, and for indicating response very early 
after treatment. For example, early increases in mean ADC was observed in 
liver cancers in patients receiving radiotherapy, and correlated with higher 
doses and sustained tumour response, whereas size measurements such as 
volume changes on T2 weighted images or monitoring of the largest tumour 
diameter did not [42]. In a mouse model of prostate cancer, ADC was 
successfully used to differentiate well differentiated adenocarcinoma from 
poorly differentiated carcinoma and normal prostate tissue, and cancer 
development could be predicted by locally reduced ADC before changes in 
median whole prostate ADC, nor alterations in prostate volumes were 
detected [43].  
Due to recent technical advancements in e.g. gradient systems, however, 
efforts to apply IVIM analysis are currently increasing [32]. In a recent 
study, where IVIM-DWI was used to assess the efficacy of a vascular 
disruptive agent in a rabbit VX2 liver tumour model, f and D* showed 
statistically significant decreased values already at 4 h post-therapy, and D 
showed a statistically significant increase at 24 h. Furthermore, the 
decreasing  f and fxD* (a quantity reflecting blood flow), were correlated 
with lower tumour volume progression during a one-week follow-up, and 
comparisons with histology demonstrated statistically significant and 
positive correlations between f and fxD* and micro-vessel density and 
between D and necrotic tissue fraction [44]. The use of IVIM-DWI should 
also increase the sensitivity of measurements of diffusion related tumour 
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characteristics. For example, Rijswijk et al. [45] compared D and ADC in 
soft tissue tumours in patients with different types of tumours, and in 
different locations, and found that D could separate malignant from non-
malignant tumours, whereas ADC could not. 
In an IVIM-DWI study of a mouse mammary carcinoma model a 
statistically significant, positive correlation between fxD* and interstitial 
fluid pressure (IFP) was found, which makes IVIM-DWI an interesting 
alternative to the invasive techniques previously required for IFP 
measurement [46]. 
Dynamic contrast enhanced MRI 
Neo-vascularisation is critical for tumour growth, and driven by angiogenic 
factors that are expressed due to hypoxia [47]. The newly formed vessels are 
highly permeable, which cause low molecular weight contrast agents to leak 
into the extracellular extravascular space (EES). Dynamic contrast enhanced 
MRI (DCE-MRI) exploits this leakage by measuring the concentration of 
contrast agents, and hence the signal enhancement caused by shortened T1 
relaxation, in the EES. It can thereby provide biomarkers of hypoxia, and it 
is widely used clinically for early evaluation after anti-angiogenic therapies 
[25, 47]. It provides important information on tumour properties that affect 
delivery of therapeutic agents to the tumour cells, such as the tumour spatial 
distribution of vascularity, local vessel structure and function, perfusion, 
diffusivity in the EES and blood volume [48, 49]. Since these properties may 
vary throughout the tumour, and thereby in part explain the heterogeneous 
response of tumour therapies, the DCE-MRI signal time-intensity curve 
(TIC) has been extensively studied using both semi-quantitative and 
quantitative approaches, and it provides spatially resolved imaging 
biomarkers of relevance to therapy [25, 50]. For example, the tumour uptake 
of radionuclides in a rat model of pancreatic cancer correlated with semi-
quantitative DCE derived parameters reflecting exchange rate between blood 
plasma and EES [50]. In a rat model of prostate cancer, tissue oxygenation 
measured using pimonidazole stained tissue sections correlated with TIC 
behaviour; fast changes in the TIC correlated with adequate perfusion, 
whereas slow changes were found in hypoxic regions [51]. It has further 
been suggested that DCE-MRI may provide biomarkers for IFP, which is 
associated with clinical outcome in many types of cancers [52-54].  
Relaxation MRI 
A driving force of the development of MRI was the discovery that tumours 
had shorter T1 relaxation time than most normal tissue. T1 describes the 
recovery of longitudinal magnetization after excitation by an RF pulse, and it 
is shortened by the presence of macromolecules. T1 should thus be 
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influenced by treatments affecting the molecular content of tumour tissue 
water. A study using anti-angiogenic therapy of an ovarian tumour mouse 
model showed a statistically supported increase in T1 already 2 days after 
onset of therapy, and it was still increased after 14 days [55]. In a study on 
patient with glioblastoma, T1 could be used to predict tumour progression 
[56]. 
Transversal decay of magnetization after excitation is described by the T2 
relaxation time. T2* is the corresponding constant if no spin echo is used to 
re-phase the signal decay due to magnetic field inhomogeneity. 
Deoxyhaemoglobin is paramagnetic and the local magnetic field around 
blood with low pO2 may be affected, which in turn would reduce T2* and 
hence the MR signal. Tumour vessel abnormalities, hypoxia and 
haemorrhage could thus have an effect on the T2* value. In patients with 
colorectal liver metastases, pre-treatment T2* has been associated with 
overall survival [57].  
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Aims 
 
The overall aim of this thesis was to investigate the potential of 
multiparametric MR methods for prediction and assessment of tumour 
therapy response, based on an animal model of neuroendocrine tumour and 
treatment using 177Lu-octreotate.  
The specific aims were:  
 
 to study the possibility to use MRI methods to accurately determine 
the volume of small tumours in a limited acquisition time (I), 
 
 to improve the IVIM-MRI parameter estimates by optimizing the 
choices of model fitting algorithms and parameters (II), 
 
 to study the relations between tissue parameters derived from multiple 
MR methods and parameters derived from  histological analyses of 
the corresponding, spatially registered tumour sections  (III), 
 
 to investigate how multiple MR parameters available for response 
assessment are associated with response of neuroendocrine tumours 
receiving radionuclide therapy (IV), and 
 
 to propose potential MR derived imaging biomarkers for therapy 
response assessment (III & IV). 
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Methods  
General experimental setup 
Animals and tumour models 
This thesis is mainly based on studies on female BALB/c nude mice 
(Charles River, Japan and Germany) with xenografts of a human small-
intestine NET (GOT1 [58]) growing subcutaneously in the neck region since 
the age of four weeks. Animals were housed in a pathogen-free environment 
receiving standard diet and water ad libitum (I-IV). At the start of the MR 
experiments, tumour diameters were between 10 and 20 mm (II-IV).  
Ethics 
The Gothenburg Ethical Committee on Animal Research approved the 
studies. 
MR system  
All MR experiments were performed on a 7T MR system equipped with 
water cooled gradients of maximum 400 mT/m (Bruker BioSpin MRI 
GmbH, Germany; software: ParaVision 5.0 (I) or 5.1 (II-IV)). RF signal 
transmission and reception was achieved using a 72-mm volume coil and an 
actively decoupled, 4-channel array rat brain coil, respectively, or a 50-mm 
quadrature transmit/receive volume coil (RAPID Biomedical GmbH, 
Germany).  
Animal positioning, anaesthesia and monitoring 
Animals were imaged either in prone position using respiration triggered 
acquisitions or in supine position without respiratory triggering, but with 
tumours immobilized in a hole cut out from the supporting bed. For the latter 
setup, gel (Lectro Derm, Handelsvaruhuset Viroderm, Sweden) was used to 
improve the magnetic field homogeneity within the tumour, and the 4-
channel receiver coil was mounted under the tumour. A pressure sensitive 
pad (SA Instruments, Inc., NY, USA) placed next to the animal provided the 
signal for respiratory triggering, and was used for respiration monitoring 
during all acquisitions. Anaesthesia was maintained during acquisitions 
using a gaseous mixture of air and isoflurane (1.5-3.0 %).  
Figure 1 illustrates the setup used for most experiments in II-IV, and Figure 
2 states the animal positioning and coils used for the different experiments.  
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Figure 1. The position of the animal in the magnet bore during acquisition 
(A), with cross-sectional view in the level of the tumour (B), and custom 
made animal holder (C). This setup was used for the animals imaged in 
supine position without respiratory triggering (n=18, included in II-IV). The 
tumours were immobilized in a hole cut out from the supporting bed (arrows 
marked with 2). The magnetic field homogeneity within the tumour was 
improved by submerging the tumour in gel, and thereby offsetting the tissue-
air interface. The gel was confined by a thin plastic film separating the gel 
from the elements of the 4-channel receiver coil (4) by only a few mm. Body 
temperature was maintained using an electrical heating pad (3) under the 
animal and a circulating warm water system set to 40°C (1). Isoflurane gas 
for anaesthesia was delivered via a nose cone or a tube. The pressure 
sensitive pad used for respiratory monitoring is not shown 
MRI for tumour volume assessment (I) 
The accuracy of tumour volume estimations based on MRI was evaluated by 
comparing tumour volumes determined from T2 weighted images with the 
weight of the resected tumours. Both 2- and 3-dimensional (2D, 3D), fat 
suppressed, rapid acquisition with relaxation enhancement (RARE) 
sequences were acquired, with varying image resolution (matrix size). The 
volume estimates were based on manual delineations of the tumours and 
multiplication of the total number of tumour voxels by the voxel volume. 
The reader is referred to I for the detailed description of image acquisition 
parameters, intra- and interobserver variability, partial volume effects and 
comparisons with standard, gauge block based volume estimates. 
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MR experiments (II-IV) 
Localization and shimming 
A fast gradient-echo localizer (a.k.a. tripilot) was used for verification of 
correct tumour position (magnet isocenter), and for geometric planning of 
additional experiments. Optimization of field homogeneity was achieved by 
shimming based on a field map acquisition (Bruker MAPSHIM macro). The 
full–width-at-half-maximum was measured on the water spectral peak of a 
voxel within the tumour, and the shim procedure was repeated until it 
reached a minimum, or below 40 Hz (0.13 ppm).  
Imaging protocols 
One day prior to therapy (day -1), animals were subjected to multiparametric 
MR experiments. After tripilot acquisition and shimming, the IVIM-DWI 
was acquired. The FOV and slice locations were exported and used also for 
the subsequent T2* mapping, T1 mapping and DCE-MRI (central slice 
only). During the sixth dynamic acquisition in the DCE-MRI series, contrast 
agent was injected via a catheter inserted into a tail vein, with infusion line 
reaching outside the magnet bore. For this, a 0.1 M, 0.3 mmol/kg 
bodyweight, Gd-DTPA (Dotarem, Gothia Medical, Sweden) solution was 
used. The T2 weighted MRI experiment was acquired without slice gaps and 
with increased number of slices for complete tumour coverage. The total 
experiment time, including preparation, was typically less than 1.5 h per 
animal. The experiments were repeated on days 1, 3, 8 and 13 after treatment 
(day 0), but DCE-MRI was not performed on day 13. Figure 2 shows a 
timetable of the imaging experiments and the treatment. The detailed 
acquisition parameters can be found in Table 2 of IV.  
Treatment & radiopharmaceutical 
An injection of 15 MBq 177Lu-octreotate (IDB Holland, the Netherlands) 
was given in a tail vein on day 0. The radiopharmaceutical had been 
prepared according to instructions from the manufacturer, resulting in a 
specific activity of 26 MBq/µg octreotate. The fraction of peptide-bound 
177Lu was > 98 %, as determined by instant thin layer chromatography 
(ITLC™ SG, PALL Corporation, USA), with 0.1 M sodium citrate (pH 5; 
VWR International AB, Sweden) as mobile phase.  The 177Lu activity in 
syringes before and after injection was measured by a well-type ionization 
chamber (CRC-15R; Capintec, IA, USA). The extrapolated absorbed tumour 
dose was estimated to approximately 4.0 Gy, as previously described [59]. 
The amount of 177Lu-octreotate was chosen to result in only partial tumour 
remission.  
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Figure 2. Overview of the imaging experiments and animals. Upper pane 
(included in I): The crosses on the green bar mark the different weights (at 
resection) of the 15 tumours that had their volumes successfully determined 
from 2D, T2 weighted MRIs acquired before resection. These animals were 
imaged in prone position using the surface coil and with respiratory 
triggering. Lower pane: Imaging and treatment schedule for the 21 animals 
used in II-IV. Colours indicate which MR methods were applied (cf. figure 
legend, white = not acquired). These animals were imaged in supine position 
according to the setup explained in Figure 1, except for three animals which 
were imaged using the volume coil (indicated by VC), in prone position and 
with respiratory triggering. Animals were killed and tumour tissue was 
harvested for proteomics and histological staining after the day 1 or day 13 
imaging experiments (white bar with black cross). p = samples for 
proteomics taken from peripheral and central tumour tissue. The angle of a 
black arrow (relative to a horizontal line of angle 0) indicates the relative 
tumour volume development until day 8 (proportional to the response 
variable). #1 and #2 indicate the IVIM-DWI experiments corresponding to 
tumour example 1 and 2, respectively, shown in Figures 7 and 8. Heat maps 
of #3 are shown in Figure 9  
 17 
 
Tissue harvesting 
After the final MR experiments, animals were given a lethal i.p injection of 
sodium pentobarbitone, followed by cardiac puncture. Either the tumour was 
immediately removed and weighed (I), or it was divided and marked for 
subsequent image registration (III) and protein expression analysis (IV). 
Figure 3 describes the procedures of tissue harvesting used in III-IV. 
 
Figure 3. Tissue harvesting for histological staining, image registration (III) 
and proteomics (IV). After the final MR image series had been acquired, the 
animal was killed and placed in prone position on an operation table (B-C). 
The most central, T2 weighted image of and MRI series is shown (A), with 
arrows indicating the tumour sections that were imaged (A-B). The central 
image position is also shown by the black, solid line (B, D and E). An incision 
was made through skin and tumour in a plane parallel to the central image 
section (D, dashed, blue line). The imaged section was marked by injecting 
small amounts of green, yellow and red tissue ink on the right, dorsal and left 
tumour boarder, respectively (E). The tumour half containing the ink was 
prepared for histological staining. In the microtome, the cut surface was 
placed to face the microtome knife sweep plane, and once the tissue ink was 
visible (F), the histological sections were collected, stained, digitalised and 
registered to the MR images (III). The other tumour half (G) was further 
divided into central (c) and peripheral (p) parts for protein expression 
analysis (IV) 
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Post-processing  
Software 
Post processing such as image filtering and model fitting, as well as 
statistical calculations, were performed on PC workstations using MATLAB 
(R2008b (I), R2014b (II), R2015b (III-IV), The MathWorks, Inc., USA) 
unless otherwise stated. Both MATLAB standard and in-house developed 
scripts and graphical user interfaces were used, and relevant MATLAB 
functions will be stated in the text. For additional details, the reader is 
referred to the corresponding separate papers included in this thesis.  
Optimization of IVIM-MRI model fitting (II) 
To optimize the quality of the IVIM model parameters for the experimental 
setup and tumour model used in the present studies, both in vivo data from 
the IVIM-DWI experiments and computer simulations were used to estimate 
the parameters. Bayesian methods with three different a priori distributions 
(reciprocal, shrinkage and uniform) and three different representations of 
central tendency of the resulting parameter distributions (median, mean and 
mode) were evaluated. The SNR in tumour in the in vivo images (b=0) was 
calculated (resulting in SNR ~ 15-25), and different levels of Rician noise 
were added to the simulated parameters to evaluate performance on similar 
SNR levels (SNR = 10, 20 and 40 were simulated). The diffusion b-values 
and parameter limits used for IVIM-DWI were used also in the simulations.  
Calculation of MR parameters (III-IV) 
A 2x2 median filter was applied to all images before further post-processing 
and parameter calculations. The parameters derived from MRI examinations 
can be found in Table 2 of IV. Briefly, IVIM-DWI parameters were 
estimated using a Bayesian model fitting method with uniform prior 
distribution, whereas other model parameters were fitted using least squares 
methods. DCE-MRI parameters were semi-quantitatively determined by 
analysing the MR signal time-intensity curve after contrast injection.   
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Histology, image registration & data sampling (III) 
Histological imaging (III) 
The microtome produced 2-3 µm thick tumour sections of the tumour half 
prepared for histological analysis (Figure 3), and sets of four sections were 
collected for histological and immunohistochemical staining. One section 
was stained with haematoxylin-eosin (HE) using Tissue-Tek Prisma (Sakura 
FineTek, Sweden), another section was stained with Masson Trichrome 
(MT) using Artisan Link (Dako, Denmark). Two other sections were 
processed for immunohistochemical staining. They were pre-treated with 
EnVision™ FLEX Target Retrieval Solution (high pH; PT-Link; Dako, 
Denmark) followed by incubations using Envision Flex (Dako, Denmark). 
As primary antibodies, Ki67 (AB9260; Merck Milipore) and CD31 
(AB28365; Abcam, UK) were used. The staining was performed in an 
Autostainer Link (Dako, Denmark) following the manufacturer’s 
instructions. In each run, positive and negative controls were included. A 
Leica SCN400 Slide Scanner (40x magnification, Leica Microsystems, 
Germany) was used to digitalize the stained sections. The resulting high 
resolution histological images (0.25 x 0.25 μm2) were exported for further 
processing on a PC workstation.  
Spatial registration of MR- and histological images (III) 
Spatial registration of MR images, parameter maps derived from MR images 
and the histological images was performed for the tumours where the quality 
of histological sections and MR images/maps were satisfactory. Artefacts in 
parts of images, or lack of visual landmarks were handled by avoiding 
registration of the entire tumour in a single step. Instead, registration was 
performed sequentially on tumour sub-regions, and when data had been 
extracted (sampled) from an entire sub-region, another sub-region was 
registered and sampled.  
Data sampling (III) 
Data samples were collected by 1) automatically creating a 250 x 250 μm2 
region-of-interest (ROI) within a registered tumour sub-region, 2) 
calculating the HE index (see below) for the ROI, 3) sequentially 
transforming the ROI coordinates to corresponding positions on the other 
registered images for index calculation or extraction of the ROI mean MR 
parameter value and, 4) automatically translating the HE ROI coordinates 
for sampling of an adjacent position within the sub-region. Steps 2-4 were 
repeated until the entire sub-region was completely sampled. If another 
tumour sub-region could be registered, it was sampled according to steps 1-
4, and the process was repeated until as much of the tumour area as possible 
had been sampled. 
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Definition of histological indices (III) 
The ROI index for apoptotic activity was calculated by using a cell 
segmentation method based on previously presented principles [60] 
combined with colour thresholding. It was designed to detect cell shaped 
objects (round to oval), and the colour thresholds were used to identify only 
the tumour cells with dark stained nuclei. The apoptotic tumour cell count 
(HEcount) could thus be defined as the number of apoptotic cells per 250 x 
250 μm2 surface area, under the assumption that a dark stained nucleus 
represented a cell with condensed chromatin due to apoptosis (cf. [61]). The 
Ki67 index was determined similarly, but on Ki67 images the colour 
threshold was set to detect only cells with brown stained Ki67 positive 
chromatin. Proliferating tumour cell count (Ki67count) was thus defined as 
the number of Ki67 positive cells per 250 x 250 μm2 surface area. Figure 4 
illustrates the method for cell segmentation.  
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Figure 4. Tumour cell segmentation in HE (a) and Ki67 (e) stained 
histological sections of one of the studied GOT1 tumours. In (a), a yellow 
arrow head points at a tumour cell where the dark stained (HE positive) 
nucleus indicates condensed chromatin, typical of apoptotic cells. Arrows 
point at tumour cells not regarded apoptotic. In (b), the same image region is 
shown after automatic cell segmentation. Clearly, both apoptotic (arrow 
head) and non-apoptotic (arrows) are detected. By applying an additional 
filter based on manual adjustment of colour thresholds (c, screen capture 
from MATLAB colour segmentation application), the cells without a dark 
stained nucleus could be rejected (d), whereby the remaining, apoptotic cells 
could be automatically counted. The same procedure was applied to the 
Ki67 magnification in order to calculate proliferating, Ki67 positive tumour 
cells only (brown stained cells in e-f). Red bars indicate ~10 μm 
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Micro-vessel density (MVD) and fibrotic density (FD) were defined as the 
fraction of CD31 and MT positive area per 250 x 250 μm2 surface area, 
respectively. These indices were determined by colour thresholding only 
(Figure 5).  
 
Figure 5. Vascular endothelial cells lining the vessels in one of the studied 
GOT1 tumours are stained with CD31 (a, brown stain), and colour 
segmentation has been applied for calculation of micro-vessel density 
(magnification in b). Yellow arrows point at relatively large vessels 
surrounded by endothelial cells stained brown by CD31, where erythrocytes 
are visible within the vessels. In (c), Masson Trichrome stains fibrotic tissue 
blue, and the same region is shown in (d) after colour segmentation for 
calculation of fibrotic density. Red bars indicate ~100 μm 
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The segmentation of apoptotic and proliferating tumour cells and the colour 
thresholds used to determine MVD and FD were validated by a board 
certified pathologist before data extraction.  
Response verification (IV) 
The change in tumour volume after treatment was used to define response. 
Tumour volumes were determined from the T2 weighted images of each 
experiment, as described above and in I, and the linear regression coefficient 
of the relative tumour volumes (from day -1 to 8) constitutes the response 
variable. It should be noted, therefore, that a greater tumour volume 
regression after treatment corresponds to a lower value of the response 
variable, and vice versa.  
Spatial and temporal evaluation of MR features (IV) 
MR parameters (e.g. ADC) were evaluated both as representing tumour 
median values, and as representing median values of a particular tumour 
region only (e.g. central or peripheral tumour). In this study, annular discs 
shaped like the tumour were constructed, and data were extracted from 
regions covered by these discs. Figure 6 illustrates the construction of discs 
and extraction of data. Data were extracted from the tumour section covered 
by the single slice DCE-MRI experiment. For improved statistics of the 
other experiments, however, data from the two most adjacent slices (in total 
three slices) were also extracted, and merged with central slice data before 
evaluation. The efficacy, or importance, of the MR parameters regarding 
response assessment, was evaluated for the tumour and the five discs 
separately. Furthermore, both the pre-treatment (day-1) MR parameter 
values and the change in values over time after treatment were evaluated.  
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Figure 6. Illustration of the extraction of tumour and regional median MR 
parameter values of a subcutaneous GOT1 tumour. The central slice of the 
DWI experiment (b=800 s/mm2) is used for tumour delineation (a). The 
resulting ROI is transferred to the ADC map (b) and the median value of the 
distribution of ADC values within the ROI is extracted (c). Four additional 
identically shaped ROIs, with stepwise decreased radius, are automatically 
reproduced (d), which separates the tumour into five regions. The central 
region is designated disc 1, and the annular disc shaped regions are 
designated discs 2-5 (d). Extraction of ADC data from disc 4 is shown in (d), 
revealing lower median diffusion (1.0 μm2/ms) in this tumour region 
compared with the overall median diffusion (1.5 μm2/ms) of the tumour 
(fictional diffusion data)  
Definition of MR features (IV) 
Henceforth, an MR feature is the median value of a particular MR parameter 
in a disc or in the tumour before treatment (day -1), or the change in the 
corresponding median value from day A to day B (designated A:B or day 
A:B). The following combination of days were evaluated: A:B = -1:1, -1:3, -
1:8, -1:13, 1:3, 3:8 and 8:13. Furthermore, two models of change were 
evaluated: absolute change [value(B) - value(A)] and relative change 
[value(B) - value(A)] / value(A).  
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Proteomics (IV) 
Samples were taken from central and peripheral tumour tissue in 15 tumours 
(Figure 2). The samples were prepared and analysed using liquid 
chromatography tandem mass spectrometry (LC-MS) with tandem mass 
tagging as described in IV and [62]. Detected proteins were associated with 
biological functions using the Gene Ontology database 
(http://www.geneontology.org) [63].  
Data handling and statistics 
Associations between MR parameters and histological indices (III) 
Since samples were taken from five different tumours, where random effects 
may be present due to e.g. tissue preparation, colour threshold levels or coil 
combination, the underlying pairwise associations between MR parameters 
and histological indices were evaluated using linear mixed-effects regression 
analysis. The level of redundancy in the information provided by the 
investigated MR parameters was evaluated using agglomerative hierarchical 
clustering. 
Prior to analysis, non-normally distributed parameters were transformed 
using the Box-Cox power transformation (Matlab boxcox function), and 
pairwise deletion was used to account for missing values in the pairwise 
comparisons. A regression coefficient was considered significantly different 
from zero for p < 5.0 x 10-4 (0.05 adjusted for multiple comparisons using 
the Benjamini & Yekutieli method (q = 0.05)).  
Feature selection (IV) 
Prior to feature calculations, non-normally distributed MR parameters were 
transformed using the Box-Cox power transformation and standardized to 
mean value = 0 and standard deviation = 1. Thereafter, features were 
defined, and only those with less than 50 % missing values were analysed. 
Data imputation was used to replace missing values in the remaining 
features, where imputed values were stochastically selected from a normal 
distribution. 
The relative importance of each feature regarding response assessment was 
evaluated using the least absolute shrinkage and selection operator (lasso) 
feature selection method [64], preconditioned to better handle the high 
number of features using the supervised principal components (SPC) method 
[65]. The lasso returns the linear regression coefficient (β) of selected 
features, where a higher β magnitude thus indicates higher importance.  
 26 
 
Since many of the included features would most likely be highly correlated 
to each other (e.g. from adjacent discs), and since the lasso is prone to 
arbitrarily select only one of two highly correlated features, the imputation 
and feature selection process was repeated 5000 times. The β-coefficients of 
returning features were cumulatively added, thus yielding a feature specific 
β-sum which could be related to the other features β-sums.  
Proteomics (IV) 
The evaluated protein quantity was the individual tissue sample protein 
amount normalised to the mean amount of the protein in all tissue samples. 
Non-normal protein distributions were transformed using the Box-Cox 
power transformation. Only proteins that were linearly correlated with 
response with high statistical significance (p-values < 0.01) were analysed. 
These proteins were evaluated for correlations with the MR-features with 
high β-sums. Pearson correlation coefficients are stated, with corresponding 
p-values derived from Student's t distribution under the null-hypothesis of no 
correlation at all. Multiple comparisons were corrected for using the 
Benjamini & Yekutieli method (q=0.05).  
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Results 
MRI accurately predicts tumour volume (I) 
The results in I showed that volumes determined from both 2D and 3D 
sequences were highly correlated with tumour weight at resection. 3D 
acquisitions with 1603 μm3 voxels yielded regression coefficient (r) = 0.94 
and goodness-of-fit R2 = 1.00. Evaluating small tumours only (volume < 0.2 
g, n = 10) yielded: r = 0.90, R2 = 0.98. Partial volume effects were negligible 
for the range of tumour volumes (Figure 2) and voxel sizes investigated. 
Acquisition times were drastically reduced when using larger voxels, with 
e.g. the smallest tumour (0.01 g) requiring 55, 34 and 22 minutes for 
acquisitions using 1603, 2003 and 2403 μm3 voxels, respectively. 2D 
acquisitions (slice thickness = 700 μm, in-plane resolution ~150 x 200 μm2) 
and 3D acquisitions yielded similar correlations (volume < 0.2 g: n = 9, r = 
0.94 and R2 = 0.96), but with the advantage of only a few minutes 
acquisition time for the 2D method. Interobserver variability was, however, 
increased for tumour volume delineation in 2D images (Table 2 in I).  
177Lu-octreotate induced tumour volume changes (IV) 
The 15 MBq 177Lu-octreotate treatment resulted in a range of tumour volume 
responses, from tumours shrinking to less than 50 % of baseline volume 
during the first week of follow-up, to tumours that almost showed similar 
growth kinetics as untreated GOT1 tumours (~two-week doubling time). 
After one week, practically all tumours showed increasing volumes again. 
Figure 2 in IV shows the therapeutic effect on individual tumour volumes of 
the 21 tumours studied in II-IV. The linear regression coefficient of the 
relative tumour volumes (from day -1 to 8), i.e. the response variable, is 
indicated for each tumour in black arrows in Figure 2. 
Optimal method for Bayesian IVIM-MRI parameter estimation (II) 
Examples of parametric maps from Bayesian model fits to data acquired in 
vivo are shown in Figure 7, with corresponding parameter distributions 
summarized in Figure 8. 
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Figure 7. Parameter maps of D, f and D* of a single tumour section 
constructed using different combinations of prior distribution (uniform, 
reciprocal and shrinkage) and central tendency measure (mean, median and 
mode) and for two of the five tumours analysed in II. Both tumours had an 
initial size of approximately 600 mm3, and responded similarly to therapy (cf. 
Figure 2). The display ranges are D: [0 2] μm2/ms, f: [0 0.4] and D*: [0 50] 
μm2/ms (adapted from II) 
 
Figure 8. The distribution of the parameters displayed in Figure 7 are shown 
using the upper, middle and lower quartile (adapted from II) 
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Visual inspection of the parametric maps of D, f and D* reveal that the 
reciprocal prior results in noisy estimates for most combinations of 
parameters and measures of central tendency (Figure 7). This is confirmed 
by the magnitude of the error bars for the reciprocal prior in Figure 8. The 
shrinkage prior resulted in less noisy parameter maps (Figure 7), with 
narrow distribution (Figure 8), but yield either high f or low D* or vice versa 
in the two example tumours. When comparing parameters from all five 
tumours, the uniform prior seems to vary less regarding the absolute level of 
the parameters (partly shown by the two examples in Figure 8). In general, 
the choice of central tendency affected the absolute level of the parameters, 
but most often only to a small extent (partly shown in Figure 8). Of the 
priors assessed, the uniform prior yielded the most stable results, but  
combined with mean or median representation it tended to give little or no 
information on the D* parameter (Figure 8). 
In general, the results from the simulations were in agreement with the in 
vivo results, and are further evaluated in II. In brief, the estimation error 
(difference between estimated and simulated value) for D with uniform prior 
was symmetrically distributed around zero, whereas the reciprocal prior 
induced a bias. For small simulated f, estimated f was slightly overestimated 
by the uniform prior combined with mean and median representations, 
whereas mode showed no such trend. With a reciprocal prior, f was severely 
underestimated for all measures of central tendency, particularly for mode 
representation at low SNR. 
MR parameters reflect important tumour biology (III) 
Histological heat maps show tumour heterogeneity (III) 
The combination of the algorithm for cell detection and colour thresholding 
resulted in adequate identification of apoptotic cells in the HE images and 
proliferating cells in the Ki67 images (Figure 4). Fibrotic tissue and vascular 
endothelial cell presence were also adequately identified in the MT and 
CD31 images, respectively (Figure 5). Heat maps of the histological indices 
HEcount, Ki67count, MVD and FD revealed highly heterogeneous and 
markedly different patterns in contiguous histological images (Figure 9).  
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Figure 9. HE section, heat maps and selected MR parameter maps from 
one of the studied GOT1 tumours that responded to therapy by markedly 
reduced tumour volume (marked with #3 in Figure 2). Delineations on MR 
parameter maps show tumour boundaries. Note the difference in tumour 
shape between histological sections/heat maps and e.g. T1 map. A typical 
landmark for registration is visible in the lower left part of the tumour which, 
e.g., show low intensity on IS and SER maps, but high intensity on MVD 
heat map 
Correlations between MR parameters and histological indices (III) 
The results from the linear mixed-effects regression analysis are summarized 
in Figure 10. Based on statistical significance, HEcount could be predicted 
by three DCE-MRI parameters (TOP, TTP and BE), Ki67count could be 
predicted by one DCE-MRI and one relaxation parameter (IS and T1), as 
could MVD (SEmax and T1) and FD could be predicted by one IVIM-DWI 
parameter (f). Other strong correlations that almost reached statistical 
significance were also found, e.g. between HEcount and SER or MVD and 
AUCn.  
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Figure 10. Regression coefficients (upper plot) with corresponding p-values 
(lower plot) for pairwise associations of MR parameters and histological 
indices found in III. The correlations are based on 1821 samples from the 
five tumours, where each sample contain four histological indices and 20 MR 
parameters extracted from a 250x250 μm2 tumour region. Linear mixed-
effects regression was used to account for random effects by e.g. coil setup, 
tissue preparation or colour threshold levels. A vertical dashed line in the 
lower plot shows the p = 0.05 level adjusted for multiple comparisons. The p-
value for IS vs. Ki67count was 1.5e-23 (adapted from III) 
Uniqueness of MR parameter information (III)  
The dendogram of the cluster analysis of MR parameters is shown in Figure 
11. It demonstrates similarities between CER and SEmax, which was 
expected due to their similar definitions. Another expected similarity was 
found between D and ADC, as well as between D* and D*xf. Viewed from a 
perspective of differences (from above in Figure 11), some parameters were 
regarded more different from others regarding information content, like the 
single parameters WO, NS, T1 and T2*. Others formed groups of mutual 
information content, but with little in common with other parameters, such 
as the perfusion related IVIM-DWI parameters (f, D* and fxD*) and the 
diffusion parameters (D and ADC). One group was formed with many DCE-
MRI parameters. 
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Figure 11. The results of the cluster analysis of the MR parameters is shown 
in the dendogram. The single linkage distance measure is used. Adapted 
from III 
Spatiotemporal MR analysis predicts therapy response (IV) 
T2 weighted anatomical imaging of tumour response (IV)  
T2 weighted images of two tumours, acquired before and repeatedly after 
therapy, are shown in Figure 12. The images demonstrate the excellent 
tumour-to-background tissue contrast that is achievable using T2 weighted 
imaging. However, although the tumours responded very differently to 
therapy, neither the heterogeneous tumour patterns, nor the way the patterns 
change over time reveal any obvious differences between the tumours by 
visual inspection.  
 33 
 
 
Figure 12. T2 weighted images of a central tumour section in two of the 
animals in IV. The fluctuating dark and bright intra-tumour regions are 
manifestations of tumour heterogeneity. The gel used for improved field 
homogeneity is visible as bright regions under the tumours. Left images, 
framed in red, shows a tumour that continued to grow after treatment. On 
day -1(a), the tumour volume was estimated to 241 mm3 (100 %). On days 1 
(b), 3 (c), 8 (d) and 13 (e), it reached 104, 109, 136 and 173 %, respectively. 
The tumour to the right, framed in green, was initially 611 mm3 (100 %), but 
after treatment it decreased to 96, 91, 73 and 81 %, on days 1 (g), 3 (h), 8 (i) 
and 13 (j), respectively. The heterogeneous patterns of the tumours on day -
1 are only slightly altered over time, and reveal no obvious differences that 
can be used to separate the differently responding tumours. This illustrates 
the necessity of acquiring additional MR parameters for evaluation of 
biological response to therapy. Note that the sizes of the tumour images 
were rescaled for better visualization  
  
 34 
 
Correlation between MR features and response (IV) 
Many MR features showed significant correlation with response, and each 
individual correlation is shown in Figure 4 in IV. In general, apart from an 
occasional change of sign, the definition of change of a parameter value over 
time as absolute or relative had little effect on correlation coefficients (<0.1, 
data not shown). Some correlations, however, (e.g. for SER features) were 
more affected and showed substantially different correlation coefficients 
depending on definition.  
Highly efficacious MR features found in regional and early 
evaluation (IV) 
The MR features reaching a relative cumulated lasso regression coefficient 
(β-sum) over 0.05 are shown in Figure 13 (the 0.05 display limit was 
arbitrarily chosen for improved visualization). The feature reaching highest 
β-sum was SER measured peripherally (disc 4) on day -1, with 
approximately twice the β-sum of the second most important feature, which 
was the relative increase in D in the same disc on Δday -1:3. Five of the MR 
parameters represented in Figure 13 required disc separation in order to 
reach the display limit (e.g. IS), whereas tumour median sufficed for display 
of the other 7 MR parameters. Interestingly, a lot of information regarding 
therapy response seems to be available very early after treatment, since a 
total of 24 features, based on 10 MR parameters, were displayed on day -
1:1. The pre-treatment tumour volume was strongly correlated with the 
response variable (correlation coefficient = -0.60), suggesting that treatment 
effect improved with tumour volume. Surprisingly, however, it did not reach 
display limit in Figure 13. 
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Figure 13. The relative magnitude of the cumulated lasso regression 
coefficients over 5000 imputations, the β-sums, for individual MR features is 
indicated by colour, with disc number and MR parameter indicated by the 
sections of the pie chart. Hash-tag (#) indicates that the feature was based 
on relative change (cf. fig. 12 for sign of correlation). Note that the change in 
SE60 between day -1 and 1 (-1:1) in disc 3 differs from disc 1 and 2 
regarding definition of change. For clarity of display, features with relative β-
sum < 0.05 are not displayed. Adapted from IV 
Spatiotemporal evaluation of selected MR parameters  
The development over time for MR parameter values in different tumour 
regions (disc 1-5) often differed profoundly between tumours that showed a 
decreasing volume during the first week after treatment (positive response 
variable, cf. arrows in Figure 2), and tumours that only showed a reduced 
growth rate (negative response variable). These two groups will henceforth 
be referred to as shrinking and stabilising, respectively, and some interesting 
examples are shown in Figures 14-16.   
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Figure 14. Development of IS (upper) and T2* (lower) in the five discs over 
time for shrinking (blue) and stabilising (red) tumours. For each day, central 
tumour values (disc 1) are displayed to the left, and disc numbers are 
increasing to the right. The median, 25th and 75th percentiles are 
represented by the middle point, lower and upper bold lines, respectively. 
Some extreme values and outliers have been left out for display purposes. 
Two medians are significantly different at the 5% significance level if the 
intervals marked by the triangular marker do not overlap 
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Figure 15. Development of T1 (upper) and SER, AT and TOP (lower) in the 
five discs over time for shrinking (blue) and stabilising (red) tumours. For 
each day, central tumour values (disc 1) are displayed to the left, and disc 
numbers are increasing to the right. The median, 25th and 75th percentiles 
are represented by the middle point, lower and upper bold lines, 
respectively. Some extreme values and outliers have been left out for 
display purposes. Two medians are significantly different at the 5% 
significance level if the intervals marked by the triangular marker do not 
overlap 
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Figure 16. Development of D and f in the five discs over time for shrinking 
(blue) and stabilising (red) tumours. For each day, central tumour values 
(disc 1) are displayed to the left, and disc numbers are increasing to the 
right. The median, 25th and 75th percentiles are represented by the middle 
point, lower and upper bold lines, respectively. Some extreme values and 
outliers have been left out for display purposes. Two medians are 
significantly different at the 5% significance level if the intervals marked by 
the triangular marker do not overlap 
Biology supports MR findings (IV) 
The LC-MS analysis yielded expression ratios for 5381 different proteins, 
whereof 104 correlated strongly with the response (p < 0.01) and were 
further evaluated. 68, 28 and 8 of the proteins were found in central only, 
peripheral only and both central and peripheral tumour samples, 
respectively. Sixty-six of the proteins could be found in different categories 
of biological processes that are related to response to radiation according to 
the Gene Ontology database. The protein from each category that was most 
strongly correlated with response was further evaluated, and of these, two 
proteins were strongly correlated strongly also with MR features of high 
importance (high β-sums), namely CATA (Catalase, encoded by CAT) and 
CCD89 (Coiled-Coil Domain Containing 89, encoded by CCDC89).  
The pre-treatment SER in disc 4 (highest β-sum feature) and centrally 
sampled CCD89 were highly correlated (correlation coefficient (r) = -0.9 
and p-value corrected for multiple comparisons (pc) = 0.03) CCD89 is a 
protein associated with DNA damage & repair, proliferation, and cell cycle 
arrest. The relative increase in D in disc 4 on Δday -1:3 (2nd highest β-sum 
feature) and peripherally sampled CATA, a protein associated with oxidative 
stress, proliferation, cell cycle arrest, and apoptotic cell death, were also 
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significantly correlated (r = -0.86, pc = 0.03*). Additional correlations that 
did not quite reach statistical significance are listed in IV. Interestingly, the 
tumour volume prior to therapy, which was strongly associated with 
response, did not correlate significantly with any of the MR features or 
proteins evaluated.  
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“It is not the strongest of the species that survive,  
nor the most intelligent, but the one most responsive to change.”  
Charles Darwin 
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Discussion  
Tumour volume for response verification 
A decreased viable tumour mass may indicate that the tumour responds to 
therapy. However, as discussed in I, the use of the size of the tumour mass 
as a measure of therapeutic effect is not unproblematic. The clinical tumour 
size assessment methods typically rely on measurements of tumour 
diameters, either externally on palpable tumours, or on e.g. images from CT 
or MRI [66]. This rough estimate of viable tumour volume is problematic for 
non-spherical or irregular tumours, as well as for disseminated disease with 
many tumours. Apart from this, a changing tumour size from diagnosis to 
evaluation of therapy effect is really only indicative of disease progression if 
the doubling time of the tumour is known [67, 68]. In this thesis, however, 
the main interest was not long-term effects, but rather the immediate 
radiobiological effects on tumour tissue, and the associations to MR derived 
parameters. Therefore, repeated, short-interval tumour volume estimation is 
probably a reasonable surrogate marker of tumour response. It should also be 
noted that the purpose of the treatments in the studies was only to induce a 
suboptimal therapeutic effect, to enable further measurements on the 
tumours and to correlate MR data with different levels of therapeutic effects 
expected from heterogeneous responses. 
Assuming that MR based tumour volume estimations would provide a more 
sensitive and accurate response verification method compared with external 
measurements of tumours dimensions using e.g. gauge block, we studied the 
performance of such methods relative to the golden standard ex vivo 
determination of tumour volumes. The T2 weighted RARE sequence was 
used to acquire tumour images since the use of 180° refocusing pulses makes 
it robust to geometrical distortions. However, the accuracy regarding volume 
assessments still warranted investigation since it could be affected by pixel 
smoothing effects due to turbo factors and partial volume effects from 
insufficient voxel sizes in 3D acquisitions, in addition to slice profiles in 2D 
acquisitions. 
Acquisition time is often limited both in the clinical and pre-clinical 
situation, especially when additional experiments are to be conducted within 
the same imaging session. This makes 2D sequences suitable since they 
require only a fraction of the time required by 3D acquisitions, especially for 
large tumours requiring large matrix sizes. We found that 2D acquisitions 
were adequate to produce high correlations with resected tumour volumes, 
but that the interobserver variability increased when tumours were very 
small. This was probably due to partial volume effects. One remedy would 
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thus be to decrease slice thickness if allowed by the slice selection gradient 
performance and SNR. However, these considerations are only necessary if 
the range of tumour volumes in a particular study includes both very small 
and very large tumours. If all tumours are really small, 3D methods should 
be preferred. T1 weighted acquisitions are generally faster than T2 weighted 
acquisitions, but often require contrast injections for proper visualization of 
tumours. 
Other imaging modalities can be used for non-invasive tumour imaging, but 
requirements on spatial resolution makes some more interesting for tumour 
volume measurements, such as micro-CT for small animal studies. Micro-
CT has shown excellent results regarding tumour volume assessment, with 
only a few minutes of acquisition time [69]. However, CT does not offer the 
same versatility as MR regarding tumour applications, and it often requires 
contrast injections. The ionizing radiation used by CT inevitably results in an 
absorbed dose to the tumour, typically 0.1-0.3 Gy per examination, which 
may confound results in therapy response assessments [70, 71]. 
The 2D acquisition method discussed above was chosen for tumour volume 
assessment in IV. The tumours volumes determined for the 21 included 
animals were in general larger than 200 mm3 (0.2 g) (median estimated 
tumour volume day -1: 460 mm3, range: 137 to 689 mm3) throughout the 
study, and it is therefore likely that the actual tumour volumes were of 
adequate size for the 2D method (cf. I). Only 3/21 tumours were smaller 
than 200 mm3 on the day -1 measurement, and only 2 tumours reached a 
volume < 100 mm3 after treatment. The absolute changes in volume between 
days were, however, often smaller than 200 mm3, but errors in the response 
variable imposed by partial volume effects should be low since response was 
defined by the regression coefficient of several measurements, which should 
have an averaging effect on the estimates.  
Model parameter optimization 
Some MR parameters included in this thesis were estimated using models of 
the MR signal behaviour under different conditions. The IVIM model 
describes the diffusion weighted MR signal behaviour for different levels of 
diffusion weighting, and it differs from the other applied models due to the 
compartmentalization of different diffusion phenomena, which makes it bi-
exponential [35]. A minimum of three model parameters (D, f and D*) needs 
to be estimated. We investigated several methods to achieve proper quality 
of the estimates, including fitting of all three parameters simultaneously 
using non-linear least squares methods, stepwise fitting of D using a simple 
mono-exponential model, followed by fitting f and D* using the first method 
with D fixed, and we also investigated the Bayesian approach described in II 
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(data only shown for the Bayesian approach). The latter was superior 
regarding the quality of f and D* in most situations.  
At the SNR levels achievable in diffusion weighted imaging, where MR 
signal is intentionally destroyed by the diffusion gradients, the choice of 
prior distribution in particular, but also of central tendency representation, 
becomes very important for Bayesian model fitting. This was confirmed by 
the results of this study, where the choice of prior distribution was found to 
have a significant impact. The uniform prior resulted in more stable 
parameter estimates in both simulations and in vivo experiments. The choice 
of central tendency representation was less important for estimating D and f, 
whereas mode representation seemed to be required for D* parameter 
estimates with acceptable errors. The results of this study emphasise the 
importance of reporting not only acquisition parameters such as the b-values, 
but also which methods were used for model fitting in IVIM-DWI studies, 
since this should be taken into account when comparing results from 
different studies. 
MR methods for response assessment 
The remainder of this discussion will mainly focus on MR parameters that 
were found interesting in III and IV, and highlight those that seem 
promising as surrogate biomarkers for biological processes of importance for 
177Lu-octreotate therapy on small intestine NETs.  
The association between MR parameters and biological tumour features 
represented by histological findings were evaluated in III (Figure 10). In 
general, the MR parameters that were significantly correlated with HEcount 
and Ki67count were those reflecting rates of contrast agent delivery to tissue 
and exchange rates between tissue and vasculature, i.e. parameters 
describing perfusion, and higher perfusion was related to increased HEcount 
and KI67count. Interestingly, the perfusion fraction (f) was positively 
correlated with FD, and negative correlations were found between MVD and 
MR parameters reflecting the amount of contrast agent reaching the tissue.  
We expected to find correlations between diffusion parameters D or ADC 
and histological parameters reflecting parameters that affect cell density, but 
we did not. When data was re-evaluated with information from IV, however, 
it became clear that the diffusion was only transiently increased on day 3, 
whereas correlations with histology were evaluated from measurements on 
day 1 and 13. A temporal mismatch between the condensation of chromatin 
measured on histology and subsequently increased diffusion due to reduced 
cell density, measured with DWI-MRI, may thus confound these types of 
correlations. 
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On a statistically significant level, three DCE-MRI parameters (TOP, TTP 
and BE) were able to predict HEcount, one (SEmax) was able to predict 
MVD and one (IS) was able to predict Ki67count. In DCE-MRI, a contrast 
agent is i.v. injected during acquisition, and the increased signal intensity in 
an image pixel is assumed to be proportional to the contrast agent 
concentration in the EES [72, 73]. By analysing the signal time-intensity 
curve (TIC), information on micro-vascular structure and functionality, as 
well as tissue characteristics that affect the delivery of therapeutic agents to 
the tumour cells can be acquired from each pixel. The vascular density sets 
an upper limit for the amount of oxygen, nutrients and pharmaceuticals that 
reach the tissue, and thereby the cells of a tumour, but the functional 
properties of the vessels may be of even more importance for successful 
delivery [50, 74-76]. For example, studies on both prostate and pancreatic 
tumour models showed that the uptake of radiolabelled tracers correlated 
with functional DCE-MRI parameters that reflect perfusion and trans-
endothelial transport (e.g. TTP, IS, SE60, WI and WO), whereas weaker 
correlations were found for contrast agent amount-related parameters (e.g. 
AUCn, CER and SEmax) [50, 76]. This is a possible explanation to the 
apparent mismatch between MVD and Ki67count observed in the heat maps 
in Figure 9. Proliferative activity requires supply of nutrients and oxygen 
and thereby vasculature, but MVD may be more related to angiogenesis and 
VEGF expression in tumours, than to the actual perfusion [74, 77, 78]. 
Histologic staining for vascular functionality, such as the combined staining 
for endothelial cells and pericytes, the latter required for proper vascular 
function, may better match information on proliferation [78]. 
A statistically significant and positive correlation was found between initial 
slope (IS) and Ki67count (p = 1.5x10-23) (III). IS mostly describe the initial 
phase of the TIC, and is a functional measure that relies on the blood 
perfusion, the extravasation of contrast agent from the vascular lumen to the 
EES and, to some extent, the volume of the EES [73, 79]. The extravasation 
rate depends on the micro-vessel permeability and surface area, but the 
angiogenic and immature vasculature of tumours makes permeability 
abnormally high, and combined with the low molecular weight of the 
contrast agent, IS is more likely to reflect perfusion than vessel permeability 
and surface area [25, 73, 80]. It seems reasonable that the most proliferative, 
or viable, tumour cells were found in regions of adequate perfusion, since 
they would require efficient delivery of oxygen and nutrients. It is thus 
possible that low IS indicates hypoxia. We did not perform histological 
staining for hypoxia, but it has been associated with long TTP and TOP in 
prostate cancer in rats, whereas normoxic regions showed short TTP and 
TOP Cho, Ackerstaff [51]. Long TTP and TOP should correspond to low IS. 
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In fact, IS and TOP demonstrated a statistically significant and strong 
negative correlation in our data (not shown).  
Based on our data, the feature selection method regarded IS important for 
response assessment (IV), particularly in peripheral tumour (disc 4) and for 
very early assessment (day -1:1) or prediction of response (day -1) (Figure 
13). Tumours with lower IS values in disc 4 prior to therapy responded with 
decreasing volume, whereas those with higher values only stabilised. 
Enhancement in peripheral tumour only has been correlated with reduced 
tumour response after radiotherapy in cervical cancer patients, whereas 
homogeneous enhancement indicated better response. On histological 
evaluation, increased permeability and abundant cancer cells were found in 
responding tumours, as opposed to increased fibrosis in non-enhancing 
regions of non-responding tumours [81, 82]. In our study, the shrinking 
tumours had similar IS in central and peripheral tumour on day -1, whereas 
stabilising tumours had significantly lower central IS (Figure 14). Adequate 
perfusion throughout the tumour may have provided access to the 
therapeutic agent, which may explain the volume reduction. However, it 
does not explain the lack of volume reduction in stabilising tumours, which 
seem to have higher IS in most parts of the tumours. It thus seems like 
tumours that were only stabilised were somehow more radioresistant.  
Several other highly interesting differences were found between the 
shrinking and stabilising tumours prior to therapy, which may offer 
explanations to the different response and/or provide potential biomarkers 
for tumour response. For example, compared with shrinking tumours, the 
stabilising tumours had a markedly higher T2*, shorter TOP and higher SER 
throughout the tumour, and a lower D but higher T1 in central tumour 
(Figures 14-16). Interestingly, there was also a positive correlation between 
tumour size before treatment and response (IV), meaning that larger tumours 
showed greater relative volume reduction after therapy. One hypothesis is 
that stabilising, i.e. smaller tumours receive less absorbed tumour dose, since 
the dimensions of the tumour is more comparable with the range of the 
emitted beta particles. 
T2* is sensitive to the presence of paramagnetic deoxyhaemoglobin due to 
dephasing of transversal magnetization, and T2* has been positively 
correlated with partial oxygen pressure (pO2) in tumour tissue [83, 84]. This 
would imply that the pO2 was lower in the shrinking tumours than in the 
stabilising tumours prior to therapy (Figure 14), which contradicts the fact 
that radiotherapy is more effective in well oxygenated tumours. However, if 
a higher number of tumour cells are viable and proliferating, it is possible 
that the generally high consumption of oxygen is causing the increased 
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deoxyhaemoglobin levels in the shrinking tumours, resulting in reduced T2*. 
The immature and chaotic vasculature of tumours may not be able to sustain 
pO2 levels, or reduce deoxyhaemoglobin levels, under such highly oxygen 
demanding conditions, but there may still be sufficient amount of oxygen for 
cell viability and adequate response [85]. Rodrigues et al. [86] investigated 
the association between pre-treatment R2* (=1/T2*) and response to 
radiotherapy in a rat prolactinoma and a mouse fibrosarcoma tumour model. 
They found that the model with lowest pre-treatment T2* (prolactinoma) 
responded with tumour volume reduction, whereas the other tumours did 
not. Furthermore, among the individual prolactinomas, there was a linear 
relation between pre-treatment R2* and volume reduction. These results are 
thus in agreement with our results, even though they used a different tumour 
model, and that there were some other discrepancies between the studies. 
They used x-rays and were thus independent of adequate delivery of the 
pharmaceutical, a higher absorbed tumour dose (15 Gy) and a 4.7 T MR 
system, which may influence susceptibility effects of the deoxyhaemoglobin.  
Lower T2* has also been associated with lower blood flow and blood 
volume, and regions with reduced oxygenation are often characterized by 
reduced vascularization and delayed and persisting signal enhancement [51, 
87]. It is thus possible that the shrinking tumours are homogeneously, but 
less supplied with blood flow, although adequate for sustained proliferation. 
This is supported by the fact that IS was lower in the greater part of 
shrinking tumours, but also by the higher TOP (delayed enhancement) and 
lower SER (relatively high late enhancement) in these tumours (Figure 15). 
As opposed to normal tissues, blood flow and glucose metabolism of 
tumours are not necessarily linearly correlated. For example, a high 
metabolism to blood flow ratio was observed in locally advanced breast 
cancer patients prior to chemotherapy, as measured by 18F-FDG and 15O-
water PET, respectively. The ratio was reduced to close to normal tissue 
ratios in patients responding with reduced tumour burden whereas blood 
flow was less affected, suggesting a reduced number of metabolically active 
tumour cells [88]. This would explain the sudden, significant increase in T2* 
in the shrinking group on day 3 of our study (IV), since decreased 
metabolism due to fewer viable cells would produce less deoxyhaemoglobin. 
Our results also indicate early reduced blood flow, based on the generally 
decreasing IS and increasing AT and TOP on day 1 and 3 (Figures 14-15). 
The pre-treatment signal enhancement ratio (SER) in rather peripheral 
tumour (disc 4 in particular) was found to be very important for tumour 
response to 177Lu-octreotate therapy (IV). It was negatively correlated with 
HEcount and almost reached statistical significance (IV). SER decreased 
significantly in most parts of the shrinking tumours (disc 1-4), but only in 
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disc 3-4 in stabilising tumours. SER is the ratio of early to late relative signal 
enhancement, and it has been closely correlated with the better understood 
pharmacokinetic redistribution rate constant kep, which in turn has been 
correlated with histologic grade and prognosis in breast cancer [89-91]. In 
patients undergoing neoadjuvant chemotherapy for locally advanced breast 
cancer, SER correlated positively with changes in glucose delivery to tumour 
tissue, as estimated by 18F-FDG [92]. Others have verified that decreased 
SER correlates with decreased glucose delivery by 18F-FDG PET, and 
decreased blood flow by 15O-water PET, but no significant correlation was 
found between SER and glucose metabolism [93].  
A decreased SER thus indicates increased apoptosis, which seems reasonable 
in the shrinking tumours (Figure 15), and it is supported by a previous study 
on the same tumour model, where apoptosis was significantly increased day 
1 and 3 after treatment using 30 MBq 177Lu-octreotate [94]. On days 7 and 
13, the apoptotic count was lower, as well as the number of tumour cells.  
It thus seems like SER is another promising biomarker for perfusion effects 
in NETs, with possible applications also in imaging of apoptosis, and since 
its definition is based on the relative enhancement at two distinct time 
points, it may provide information that is not provided by IS and vice versa. 
SER may be advantageous to kep since it does not require time consuming 
T1 mapping, nor does it require estimation or measurement of the arterial 
input function.  
The longitudinal relaxation time constant T1 showed modest but statistically 
significant, negative correlations with MVD and Ki67count (Figure 10) 
(III). Although the feature selection method did not regard it as one of the 
most important parameters to monitor for this combination of tumour model 
and therapy method (IV), there was a clear separation between tumour 
shrinking and tumours only stabilising. Tumours shrinking had lower T1 on 
all days and discs, there was a pronounced, almost linearly increasing T1 
from peripheral to central tumour in stabilising tumours, and on day 8, this 
T1 gradient was reduced, and shrinking tumour T1 was decreased (Figure 
15). 
T1 is sensitive to the molecular microenvironment of the water protons, in 
particular macromolecular concentration. In tumours, vessel permeability 
allows plasma proteins to leak to the EES where they are retained due to 
limited lymphatic drainage, and T1 is thus reduced. Treatments inhibiting 
angiogenesis, and thereby decreasing MVD, have resulted in increased 
tumour T1 [55, 56]. This may be due to the reduced number of 
macromolecules that were previously involved in vascular remodelling, 
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growth factor signalling etc., but also due to typically reduced vascular 
permeability, or vascular normalisation, that hinder protein leakage [77].  
On a mouse model of ovarian adenocarcinoma, anti-angiogenic therapy 
increased T1 but decreased micro-vessel density and proliferation 
(determined from CD31 and Ki67 staining) [55]. These results support our 
findings regarding the association between T1, MVD and Ki67count, but we 
did not observe an increased T1 after therapy (Figure 15). Instead, T1 was 
rather unchanged between day -1 and 3, before the change on day 8 
mentioned above. However, we used a completely different treatment 
modality that is not directly targeting the vasculature, and there may be less 
vascular normalisation after radionuclide therapy. The lower T1 in shrinking 
tumours may indicate a higher proliferative (Ki67count) and apoptotic 
(HEcount) activity, with a high rate of tissue degradation and biosynthesis, 
which should result in high tissue concentrations of macromolecules. The 
regrowth of these tumours seen after day 8 (IV) and the sudden drop in T1 
(Figure 15), may thus indicate increased proliferation.  
An interesting observation is that before treatment the tumours that only 
stabilise in volume show an almost linear radial gradient in several MR 
parameters; with increasing radius IS increase, T1 decrease and T2* decrease 
(Figures 14-15). This effect was not observed in the shrinking tumours, 
except for a minor decrease in T2*. The finding suggests that there is 
increasing perfusion, concentration of macromolecules and 
deoxyhaemoglobin from central to peripheral tumour regions in the 
stabilising tumours. The histological associations (Figure 10) further suggest 
that proliferation and MVD are higher in the peripheral regions of these 
tumours. Radial differences in tumour characteristics have been observed in 
both animals and patients with different tumour types, probably partly 
caused by increased tumour IFP, which in turn is associated with increased 
malignancy, hypoxia and metastases [6, 10, 12, 52, 95, 96]. For example, in 
two types of human melanoma xenografts (R-18 and T-22) there were 
significantly higher degrees of hypoxia in central tumour and MVD in 
peripheral tumour, and both parameters were positively correlated with 
central IFP for IFP > 20 mmHg [52]. Gilliksrud et al. [95] investigated 
human melanoma xenografts in mice and found that a DCE-MRI parameter 
similar to the volume transfer constant of contrast agent (Ktrans) was highest 
in peripheral tumour and lowest in central tumour, and that it was negatively 
correlated with IFP. The same correlation has been found in cervical cancer 
in patients, but without reference to tumour regions [96]. With abnormal and 
leaky microvasculature in combination with inadequate lymphatic drainage, 
the IFP eventually rises to levels comparable with the intravascular pressure, 
which reduce perfusion, or even cause complete flow stasis [77]. Typically, 
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IFP is increased throughout the tumour, but rapidly decrease at the periphery 
[10, 97]. Rofstad et al. suggested that the pro-angiogenic factors that result 
from the hypoxia are transported towards the periphery by the interstitial net 
radial fluid flow caused by the central IFP, and that they promote the 
excessive peripheral angiogenesis [52].  
This offers an explanation, in addition to the tumour size, to the varying 
therapy response in the different tumours. Some may be of a more 
aggressive, resistant and angiogenic phenotype than others, and may have 
developed a higher IFP. A radial fluid flow may result in successively 
increased concentration of macromolecules and proangiogenic factors 
(decreasing T1 and increasing MVD), increased perfusion (IS), proliferation 
(Ki67count) and thereby high oxygen consumption (reduced T2*). It would 
explain the linear radial gradient of the MR parameters described above. 
However, the profound T2* gradient (Figure 14) should not be interpreted 
solely as reflecting a corresponding gradient of deoxyhaemoglobin 
concentration. Other factors are probably also involved, such as altered 
metabolism triggered by hypoxia and hemosiderin deposits. Furthermore, 
T2* is more likely linked to deoxyhaemoglobin levels in acute hypoxia, i.e. 
caused by fluctuating perfusion, and this type of hypoxia may be less 
pronounced in peripheral tumour [47].  
Nevertheless, the combined information provided by the MR parameters that 
demonstrate these radial gradients makes it reasonable to believe that they 
do reflect tumour characteristics typically associated with therapy resistance, 
such as IFP, hypoxia angiogenesis and malignant progression. It also 
demonstrate the importance of evaluating tumours on a more regional level, 
such as the discs used by us, instead of reporting an average value of the 
entire tumour. 
Statistically significant associations were found between HEcount and BE, 
TTP and TOP (Figure 10) (III). Apoptosis was more present in regions of 
short BE, TTP, TOP, and it seems reasonable that increased access to these 
regions (higher perfusion, or IS) to the 177Lu-octreotate resulted in increased 
apoptosis. We did not, however, find any association between apoptosis and 
diffusion measured by DWI-MRI. Neither did diffusion parameters correlate 
with e.g. FD, which represents acellular tissue. Possible explanations are 
unfortunate image registration or cell reorganisation due to chemical water 
extraction and rehydration during histological preparation. However, based 
on our data, it seems like diffusion measures are more suited for longitudinal 
assessments that evaluate changes in parameter values, rather than the actual 
parameter value. In IV, both D and ADC were regarded very important to 
monitor, but it was their value relative to the pre-treatment value (on day 3) 
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that was important. Figure 16 also clearly shows that there was an increased 
D in shrinking tumours on day 3, but also on day 8, most likely due to 
decreased cell density as expected after being exposed to irradiation [98]. On 
day 13, D was reduced again, which is also expected due to the regrowth 
observed at that time. The results are in agreement with a previous study on 
the GOT1 tumour model treated using 30 MBq 177Lu-octreotate. A high 
number of apoptotic tumour cells were seen on histological evaluation after 
therapy, with highest counts reached on day 1 and 3 [94]. The ADC 
parameter showed trends similar to D, and is therefore not shown. However, 
the separation between the shrinking and stabilising tumours was not as 
obvious, which may be related to the fact that ADC is more sensitive to 
perfusion effects [35].  
It should be noted that the value of BE in this study may be negatively 
biased by the relatively short duration of the DCE-MRI experiment imposed 
by a hardware limitation. The ~5 minutes of TIC monitoring may not be 
enough to accurately measure the negative slope of the curve that was 
necessary for BE calculation, but it should be adequate for TTP or TOP 
measurements.  
The perfusion fraction (f) showed statistically significant positive correlation 
with FD, and was thereby the only evaluated MR parameter that was able to 
predict the presence of fibrotic tissue (III). This makes f interesting e.g. for 
treatment verification, since fibrosis has been demonstrated in previously 
apoptotic regions after successful treatment of GOT1 and other tumour 
models [59, 94, 99].  
Furthermore, f separated shrinking from stabilising tumours on day 1 by the 
substantially increased f in the latter tumours (Figure 16). If the treatment 
had an early effect on the vasculature, e.g. pruning immature vasculature by 
killing radiosensitive endothelial cells and thereby normalizing the 
vasculature, it may have resulted in the increased f that was observed, as 
well as the less radial dependence of IS by improved perfusion in central 
tumour. Interestingly, both the pre-treatment values and the increase in f 
were similar in all discs, whereas e.g. IS clearly demonstrated decreasing 
values toward the tumour centre. This indicates that IS and f provide 
independent information on perfusion or pseudo-diffusion effects, which is 
supported also by the separation in the clustering analysis (Figure 11).  
Unfortunately, the D* estimation most likely failed in many tumours of our 
experiments, which may have affected also the estimation of f, and definitely 
fxD*. Nevertheless, the gradual development of f over time after day 1 
indicates that the effects are not due to e.g. failed parameter estimation. 
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Other factors, such as partial volume effects involving blood flow in larger 
vessels, may influence f in particular, and partly explain the different 
behaviour of IS and f [100]. A statistically significant, strong correlation was 
demonstrated between the product fxD* and IFP in a mouse mammary 
carcinoma model. IFP was lower for increased values of fxD*, and highly 
different IFP values were observed between tumours, as measured by the 
reliable but invasive wick-in-needle technique [46]. It is thus motivated with 
additional efforts to improve estimations of D*, particularly since it could be 
combined with f to non-invasively measure IFP, which would be of great 
interest in the clinics due to the many associations between IFP and 
treatment resistance [46].  
The evaluation of the results from quantitative proteomics on central and 
peripheral tumour samples verified that there are biological differences 
between central and peripheral tumour, and that these differences may be 
related to response to radiation (IV). This data supports the radial MR 
parameter gradients discussed above.  
Relatively few features based on disc 5 were considered important for 
response assessment (Figure 13), and several MR parameters that were able 
to separate shrinking from stabilising tumours seemed to abruptly converge 
in disc 5 (see e.g. T2*, day 8-13). This may be due to PVE, i.e. that data 
from normal tissue confound the disc 5 data, but it could also be an effect of 
a net transport of biological compounds to these regions. If constituents from 
the entire tumour accumulate in peripheral tumour, it may have a direct 
effect on the MR signal, but it may also trigger e.g. angiogenesis by 
accumulation of pro-angiogenic signal molecules, even if it was not 
biologically required [10, 52]. This may render the interpretation of 
associations between MR parameters and tumour biology complicated in 
peripheral tumour. 
Other, more obvious limitations in this thesis were mostly related to the 
difficulties commonly involved in spatial registration between images and ex 
vivo tissue analyses, as discussed in III-IV. A higher number of animals 
included in the analysis would have been preferred, particularly for 
improved statistics in the correlations between MR parameters and 
histological indices (III). When studies rely on the availability of tumours of 
a suitable size and radionuclides of finite half-life, as well as the availability 
to the MR system, there is a natural barrier to high numbers of study 
subjects. The sensitivity of certain MR sequences to unfavourable scanning 
conditions, such as inhomogeneous magnetic fields or low SNR, also reduce 
the number of study subjects that are finally included in the analysis. Still, 
we believe that the hypothesis seeking nature of studies like the ones 
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presented in this thesis provide adequate information for decisions on 
further, more in-depth studies of interesting findings, even if there is too few 
study subjects to make conclusions on each separate finding of this thesis.        
Perhaps more of a confounding effect than a study limitation is the fact that 
it is difficult monitor which regions of the tumour that account for the actual 
volume changes. I.e. if a tumour shrank due to successful therapy in disc 5, 
the next measurement will regard another tumour region (most likely 
previous disc 4) as disc 5. Further development of alternatives to 
longitudinally monitor specific tumour regions are required to overcome this 
confounding effect.   
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Conclusions  
Tumour volumes can be determined with high accuracy for very small 
tumours (0.01-0.1 g). 3D methods are more accurate than 2D methods but 
are very time consuming, whereas 2D methods still provide high accuracy 
and require less than 10 minutes of acquisition time, which enables 
additional imaging experiments within one MR session.  
Robust IVIM-MRI parameter estimates can be provided by the Bayesian 
model fitting algorithm, provided that the uniform prior distribution and the 
mode representation of the resulting voxel parameter distributions are used. 
However, the method needs further improvement and optimization in order 
to provide robust estimations of the pseudo-diffusion coefficient.    
There were statistically significant associations between several tissue 
parameters derived from MR methods and parameters derived from 
histological representations of the underlying tumour biology. Apoptosis, 
proliferation, microvascular density and fibrotic density could be predicted 
by the combined use of parameters derived from DCE-MRI, T1 and T2* 
quantification and IVIM-DWI.  
The multiple MR parameters evaluated demonstrated both longer lasting and 
transient effects on different occasions after radionuclide therapy. 
Pronounced radial differences were observed, and they were confirmed by 
differences in central and peripheral expression levels of proteins involved in 
radiobiological processes. Spatiotemporally resolved multiparametric MR 
assessments may provide substantial amounts of information of relevance 
for response assessment. 
Based on the results, several potential imaging biomarkers for tumour 
therapy response assessment are proposed. DCE-MRI provided parameters 
that reflect perfusion and proliferative activity in NETs, with possible 
sensitivity also for tissue oxygenation. DWI-MRI evaluated using the IVIM 
model indirectly provided information on successful therapy by alterations 
in molecular diffusion and pseudo-diffusion effects, but timing of 
measurement was critical. T2* relaxation may provide a biomarker of 
oxygen consumption by tumour cells and cells in the TME, but requires 
validation using e.g. PET methods. T1 provides information on the TME 
regarding macromolecular content, and possibly also on the interstitial 
pressure. 
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“Only those who will risk going too far  
can possibly find out how far one can go.”  
T. S. Eliot 
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Future aspects 
This thesis describes four distinct projects with the common aim of 
investigating and developing a multiparametric MR approach to predict and 
assess the response of neuroendocrine tumours subjected to radionuclide 
therapy. Several aspects of future consideration were unravelled during the 
work.  
For further understanding of the associations between MR parameters and 
tumour biology, additional methods and histological stains need to be 
studied, and they should provide information on, e.g., IFP, angiogenesis, 
oxygenation, acidosis, inflammatory status and metabolism. Preferably, such 
methods should also be non-invasive and provide spatial information, which 
would also require additional research and development. In addition to 
increased understanding of the biological mechanisms behind MR 
parameters, methods to non-invasively estimate e.g. IFP, angiogenesis and 
hypoxia would be of great value with immediate clinical implications, such 
as prognosis and treatment decision making. Other imaging methods, such as 
PET, should complement MR studies on tumours. In particular, studies 
combining T2*, SER and IS with 18F-FDG and 15O-water PET would be 
highly interesting and may provide additional understanding of the MR 
parameters related to metabolism and diffusion/perfusion. For improved 
understanding of parameters, regardless of method, measurements should be 
made also prior to therapy in order to have better a priori knowledge of their 
behaviour in the non-treated tumour.  
It is also of utmost importance to continue the development of acquisition 
and post-processing techniques of all MR methods included. IVIM-MRI 
may require extra attention before it can provide robust estimations 
regarding pseudo-diffusion effects, and optimization needs to address choice 
of b-values, diffusion gradient timing parameters, model selection 
parameters and fitting procedures. However, the biophysical specificity must 
be balanced by the clinical feasibility, which makes it important to optimise 
the imaging protocol, both regarding acquisition time and quality of 
parameter estimates. 
Contrast agents with higher molecular weights show less extravasation into 
EES in tumours, and have shown promise to provide information on tumour 
IFP. Such agents should therefore be evaluated for additional DCE-MRI 
experiments.  
MR spectroscopy is another highly interesting candidate that should be 
included in the multiparametric MR methods, since it provides information 
on the metabolism of the tumour. Ex vivo high resolution magic angle 
 58 
 
spinning MR spectroscopy should be included as a method to verify the in 
vivo findings and to provide additional, more detailed information on the 
tumour metabolism. Imaging of the tumour metabolism has also been 
enabled by the advent of dynamic nuclear polarization techniques, which 
allows in vivo hyperpolarized 13C MRI of tumours. This technique has the 
advantage over 18F-FDG PET in that is does not rely on ionizing radiation, 
and the spatial resolution is superior. It allows, e.g., imaging of treatment 
induced cell death due to the reduced flux of 13C label from pyruvate to 
lactate, and initial studies on patients with prostate cancer seem very 
promising. An interesting alternative to, or combination with, hyperpolarized 
13C MRI would be chemical exchange saturation transfer (CEST) MRI, 
which may allow imaging of e.g. intracellular pH or glucose accumulation.  
One great obstacle to overcome in the development of MR imaging 
biomarkers for tumour characteristics is to ensure proper spatial registration 
between the image voxel and the corresponding tissue voxel. Several issues 
need to be resolved before proper registration is practically achievable, 
particularly regarding the amount of work and time required per animal. If 
invasive procedures are required to map also, e.g., IFP, an additional 
dimension of the registration procedure must be accommodated. Of 
particular interest would be means to introduce fiducial markers into the 
tissue non-invasively, which were discernible both on MR images and 
histological sections, but with minimal toxic effects or local inflammation. 
Promising approaches are inert polystyrene microspheres containing iron 
oxide and fluorescent dye, or acrylic paints, such as iridescent stainless steel 
or bronze paint. Dot-shaped landmarks based on minimal injections of such 
substances are visible on MRI and histology, and follow tissue shrinkage or 
movements through histological fixation and dehydration processes. By 
injection during needle extraction, it is possible to create line-shaped 
landmarks as well, which could be used to create 3D reconstructions of 
histological sections, which allows subsequent registration of MR- and 
histological volumes. The influence of such, rather invasive, methods on the 
tumour biology under study would, however, require careful evaluation.  
Better knowledge on the radiobiological effects on tissue from 177Lu-
ocreotate therapy is required to better understand the effects observed with 
MR methods after treatment. How does e.g. heterogeneous absorbed dose 
distribution affect the response in different parts of the tumour? 
Furthermore, the dose-response relationship must be studied. Different 
amounts of activity of 177Lu-ocreotate must be studied in order to evaluate 
the MR parameters in the entire range of tissue manifestations, from 
complete response to no response at all, as expected after different dose 
levels, and improved understanding of when relevant response mechanisms 
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take place would provide better understanding of the dynamic behaviour of 
each MR parameter after therapy.  
In this work, quantitative proteomics was used to demonstrate biological 
differences in central and peripheral tumour. Future techniques to collect 
tissue for ex vivo analysis need to allow objective tissue sampling with 
refined spatial information that better match the spatial resolution of the 
tumour sub-regions being analysed, such as the discs in this work. Biological 
verification is important before multiparametric MR based biomarkers can 
be of clinical value. 
In this thesis, the potential of evaluating response locally in tumour sub-
regions, such as the discs, was demonstrated, and when MR methods and 
spatial registration procedures are improved, further refinement of the 
tumour separation into smaller regions should be evaluated. In order to 
comprehend the enormous amount of data that results from multiparametric 
methods, including MR, histology, proteomics etc., the need for methods 
that deal with the high amount of information is increased. Such methods 
exist, e.g. the feature selection method presented, but they need to be further 
optimized to the data provided by the multiple methods discussed above.  
Before the results from the works of this thesis can be translated to the 
human situation, several aspects must be considered. For example, apart 
from the biological differences, how are the associations between MR 
parameters and tumour tissue affected by the lower magnetic field strength 
in human MR systems? Are the contrast tracer kinetics comparable between 
a subcutaneously grown tumour on a mouse and a tumour in a patient 
considering, e.g., the differences in heart rate, tracer transport distances, 
tumour size, TME and vessel configuration and function?  
The exposure situation of radionuclide therapy, with prolonged irradiation, 
relatively low dose-rate and differences in radiation quality is very different 
compared with external radiotherapy. Differences in effects on MR 
parameters should be studied in order to investigate if findings from one 
irradiation type can be generalized to other types, and effects from other 
types of treatments, such as chemotherapy, should also be evaluated. 
Furthermore, tumour types other than the NET studied in this project may 
present differences in biological characteristics, such as vascularization, and 
they may respond differently to treatment, e.g. by different cell death 
modalities. It is therefore necessary to expand studies to include other 
tumour types as well, before general conclusions on MR based tumour tissue 
characterization and response assessment can be made.  
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